{"id":"354b923c-12e2-5b03-b797-e0f27d631c97","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-no-benefit-with-pembrolizumab","predicate":"preserves_measured_pool","statement":"Confirmed objective response rate was 10% with one complete and two partial responses, median progression-free survival was 2.6 months and median overall survival was 11.1 months, prior immunotherapy negatively influenced overall survival with a hazard ratio of 2.95, and the combination of Imprime and pembrolizumab is tolerable but did not improve the outcome of advanced stage non-small cell lung cancer patients who previously progressed on anti-PD-1 or PD-L1 immunotherapies.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"d0e82d5f-ff6c-5726-9249-75ed6511b133","mechanism_event_label":"Added to a checkpoint drug in patients who had already failed one, it did not help.","subject":{"id":"a04b52d4-0af9-594a-bbda-51a16406d235","slug":"imprime-pgg","display_name":"Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"drug"},"object":{"id":"ad94cfea-9646-5b72-9c22-9faa10195be5","slug":"progression-free-survival","display_name":"Progression-free survival in high-grade glioma","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"d0e82d5f-ff6c-5726-9249-75ed6511b133","stable_key":"10629adf-a816-5b7b-82db-a76bfbb946f2:bg-no-benefit-with-pembrolizumab-event","event_type":"observed_intervention","label":"Added to a checkpoint drug in patients who had already failed one, it did not help.","description":"Confirmed objective response rate was 10% with one complete and two partial responses, median progression-free survival was 2.6 months and median overall survival was 11.1 months, prior immunotherapy negatively influenced overall survival with a hazard ratio of 2.95, and the combination of Imprime and pembrolizumab is tolerable but did not improve the outcome of advanced stage non-small cell lung cancer patients who previously progressed on anti-PD-1 or PD-L1 immunotherapies.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"e1d483e1-8ffb-573f-a06e-10a7c76927bc","slug":"pembrolizumab","display_name":"Pembrolizumab","entity_type_key":"drug"},"role":"combination_partner","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"fae8ae7e-3be1-5692-898a-c3790790bfb5","slug":"objective-response-rate","display_name":"Objective tumour response rate","entity_type_key":"cellular_process"},"role":"measured_endpoint","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"a04b52d4-0af9-594a-bbda-51a16406d235","slug":"imprime-pgg","display_name":"Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"ad94cfea-9646-5b72-9c22-9faa10195be5","slug":"progression-free-survival","display_name":"Progression-free survival in high-grade glioma","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/glucan-research/39670007.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"2aad97fa3dcbfbdcedfc88a4fbcad902de0cbade16dcf3c94b26a9c6960ced38\", \"start_char\": 0, \"end_char\": 2076, \"text_sha256\": \"2aad97fa3dcbfbdcedfc88a4fbcad902de0cbade16dcf3c94b26a9c6960ced38\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Investigator-initiated multi-institutional single-arm phase Ib/II trial in previously treated patients","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Imprime PGG at the 4 milligram per kilogram maximum tolerated dose with pembrolizumab","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Single-arm with no randomised comparator, in patients who had already progressed on checkpoint blockade. Thirty patients were evaluable for efficacy.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.","comparator":null,"unit":null,"notes":"","entity":{"slug":"beta-glucan","display_name":"Beta-glucan","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Added to a checkpoint drug in patients who had already failed one, it did not help.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[bg-p39670007] Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017. (2024). https://pubmed.ncbi.nlm.nih.gov/39670007/ DOI: 10.21037/tlcr-24-346","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Advanced non-small cell lung cancer","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"9b645ce0-05b8-501f-9b9e-faffd90a3d0d","evidence_kind":"source_excerpt","locator":"Lines 333-344","start_line":333,"end_line":344,"excerpt":"### bg-no-benefit-with-pembrolizumab\nConfirmed objective response rate was 10% with one complete and two partial responses, median progression-free survival was 2.6 months and median overall survival was 11.1 months, prior immunotherapy negatively influenced overall survival with a hazard ratio of 2.95, and the combination of Imprime and pembrolizumab is tolerable but did not improve the outcome of advanced stage non-small cell lung cancer patients who previously progressed on anti-PD-1 or PD-L1 immunotherapies.\nCondition category: normal\nnutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair.\nplain_language: Added to a checkpoint drug in patients who had already failed one, it did not help.\norganism: Human\ntissue_or_cell_type: Advanced non-small cell lung cancer\nexperimental_model: Investigator-initiated multi-institutional single-arm phase Ib/II trial in previously treated patients\nlimitations: Single-arm with no randomised comparator, in patients who had already progressed on checkpoint blockade. Thirty patients were evaluable for efficacy.\nexposure: Imprime PGG at the 4 milligram per kilogram maximum tolerated dose with pembrolizumab\nevidence_span: {\"source_cache\": \"artifacts/glucan-research/39670007.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"2aad97fa3dcbfbdcedfc88a4fbcad902de0cbade16dcf3c94b26a9c6960ced38\", \"start_char\": 0, \"end_char\": 2076, \"text_sha256\": \"2aad97fa3dcbfbdcedfc88a4fbcad902de0cbade16dcf3c94b26a9c6960ced38\"}\n[bg-p39670007] Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017. (2024). https://pubmed.ncbi.nlm.nih.gov/39670007/ DOI: 10.21037/tlcr-24-346","model_system":"Investigator-initiated multi-institutional single-arm phase Ib/II trial in previously treated patients","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [bg-p39670007] Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017. (2024). https://pubmed.ncbi.nlm.nih.gov/39670007/ DOI: 10.21037/tlcr-24-346","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"74dc223d-8289-57bf-a731-d220fa017c1e","stable_key":"import-10629adf-a816-5b7b-82db-a76bfbb946f2","title":"Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"7c62f2d2f8d99b650e6dc26a505b0f053ae1c8bdb38099d4dfc0771f65287461","revision_id":"a53bb794-0a4b-525d-9cf7-22b46a5403b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}